Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC) View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-12

AUTHORS

Sunil Parimi, Misha Eliasziw, Scott North, Marc Trudeau, Eric Winquist, Kim N. Chi, Dean Ruether, Tina Cheng, Bernhard J. Eigl

ABSTRACT

Background Docetaxel is a standard first-line treatment option for men with metastatic castration resistant prostate cancer (mCRPC). Sunitinib is attractive as a maintenance therapy due to its mechanism of action, oral route of administration, and acceptable toxicity profile. We designed a phase II study of sunitinib in patients with mCRPC who responded to docetaxel. Methods Patients with responding or stable disease at the completion of docetaxel treatment received 50 mg of sunitinib on 4 week on 2 week off cycles. Treatment continued until disease progression (either by RECIST 1.1 criteria or by cancer related symptomatic progression), intolerable toxicity, start of new cancer therapy, withdrawal of consent, or death. The primary endpoint was progression free survival. Secondary endpoints included PSA response rate and safety. Results Twenty-three patients were enrolled and treated. The mean number of prior cycles of docetaxel given was 8.6 (range 4-12). The median number of cycles of sunitinib administered was 4 (range 1-11). Adverse events were generally grade 1-2 with 12 % grade ≥ 3 which were of a type and severity expected for sunitinib. Median PFS was 4.4 months (95 % CI: 1.6-5.1). Most patients had immediate PSA increases without other evidence of disease progression, with the mean increases in PSA over baseline being 197 %, 342 %, and 1437 % in Cycles 1, 2, and 3, respectively. Conclusion Sunitinib was tolerable as maintenance therapy but median PFS was significantly lower than the predefined threshold of 6 months. More... »

PAGES

771-776

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-016-0386-z

DOI

http://dx.doi.org/10.1007/s10637-016-0386-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1045234243

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27565809


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Management", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Docetaxel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphatic Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms, Castration-Resistant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrroles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sunitinib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Taxoids", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "Department of Medical Oncology, BC Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, V5Z 4E6, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Parimi", 
        "givenName": "Sunil", 
        "id": "sg:person.014436423575.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014436423575.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tufts University", 
          "id": "https://www.grid.ac/institutes/grid.429997.8", 
          "name": [
            "Tufts University, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eliasziw", 
        "givenName": "Misha", 
        "id": "sg:person.011711467574.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011711467574.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Alberta", 
          "id": "https://www.grid.ac/institutes/grid.17089.37", 
          "name": [
            "Cross Cancer Institute, Edmonton, AB, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "North", 
        "givenName": "Scott", 
        "id": "sg:person.01151470300.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151470300.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medicine Hat Cancer Centre, Medicine Hat, AB, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Trudeau", 
        "givenName": "Marc", 
        "id": "sg:person.01133654411.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133654411.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "London Health Sciences Centre", 
          "id": "https://www.grid.ac/institutes/grid.412745.1", 
          "name": [
            "London Regional Cancer Centre, London, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Winquist", 
        "givenName": "Eric", 
        "id": "sg:person.01031740163.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031740163.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "Department of Medical Oncology, BC Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, V5Z 4E6, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chi", 
        "givenName": "Kim N.", 
        "id": "sg:person.01142252161.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Alberta Health Services", 
          "id": "https://www.grid.ac/institutes/grid.413574.0", 
          "name": [
            "Tom Baker Cancer Centre, Calgary, AB, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ruether", 
        "givenName": "Dean", 
        "id": "sg:person.01305315522.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305315522.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Alberta Health Services", 
          "id": "https://www.grid.ac/institutes/grid.413574.0", 
          "name": [
            "Tom Baker Cancer Centre, Calgary, AB, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cheng", 
        "givenName": "Tina", 
        "id": "sg:person.01103355100.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103355100.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "Department of Medical Oncology, BC Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, V5Z 4E6, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eigl", 
        "givenName": "Bernhard J.", 
        "id": "sg:person.0767126500.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767126500.90"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)70025-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000667047"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdp111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002885649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdp111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002885649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.46.4149", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002989958"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(10)61389-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005976220"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-410x.2008.08327.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006573530"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa065044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007947936"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0304-3959(75)90044-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008265857"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0304-3959(75)90044-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008265857"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-014-0091-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008660056", 
          "https://doi.org/10.1007/s10637-014-0091-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(12)70477-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009666173"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clgc.2014.06.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013259124"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.45.0494", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013364059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.20.1293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013684571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0090-4295(99)00167-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015822531"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1405095", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017836241"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(10)70112-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024596205"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa060655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025111240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70479-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027103739"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa041318", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028543233"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa040720", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029249997"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.39.4767", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031092562"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.12.4487", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031178629"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1209096", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034543175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdm554", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035066248"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.48.5268", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037275515"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70184-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037354085"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/pcan.2015.53", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039566191", 
          "https://doi.org/10.1038/pcan.2015.53"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2967/jnumed.112.105007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041669007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.57.3105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044225328"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1213755", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046224838"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074847503", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082466113", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-12", 
    "datePublishedReg": "2016-12-01", 
    "description": "Background Docetaxel is a standard first-line treatment option for men with metastatic castration resistant prostate cancer (mCRPC). Sunitinib is attractive as a maintenance therapy due to its mechanism of action, oral route of administration, and acceptable toxicity profile. We designed a phase II study of sunitinib in patients with mCRPC who responded to docetaxel. Methods Patients with responding or stable disease at the completion of docetaxel treatment received 50\u00a0mg of sunitinib on 4\u00a0week on 2\u00a0week off cycles. Treatment continued until disease progression (either by RECIST 1.1 criteria or by cancer related symptomatic progression), intolerable toxicity, start of new cancer therapy, withdrawal of consent, or death. The primary endpoint was progression free survival. Secondary endpoints included PSA response rate and safety. Results Twenty-three patients were enrolled and treated. The mean number of prior cycles of docetaxel given was 8.6 (range 4-12). The median number of cycles of sunitinib administered was 4 (range 1-11). Adverse events were generally grade 1-2 with 12\u00a0% grade\u00a0\u2265\u00a03 which were of a type and severity expected for sunitinib. Median PFS was 4.4\u00a0months (95\u00a0% CI: 1.6-5.1). Most patients had immediate PSA increases without other evidence of disease progression, with the mean increases in PSA over baseline being 197\u00a0%, 342\u00a0%, and 1437\u00a0% in Cycles 1, 2, and 3, respectively. Conclusion Sunitinib was tolerable as maintenance therapy but median PFS was significantly lower than the predefined threshold of 6\u00a0months.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-016-0386-z", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "34"
      }
    ], 
    "name": "Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)", 
    "pagination": "771-776", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d777a7e30058accb7be988300a600ae5048cd325c358721885dcf811f4ed9813"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27565809"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-016-0386-z"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1045234243"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-016-0386-z", 
      "https://app.dimensions.ai/details/publication/pub.1045234243"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:43", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000363_0000000363/records_70064_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs10637-016-0386-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-016-0386-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-016-0386-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-016-0386-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-016-0386-z'


 

This table displays all metadata directly associated to this object as RDF triples.

307 TRIPLES      21 PREDICATES      79 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-016-0386-z schema:about N0211bb9d43e34d148dee27237e321534
2 N0226f7ec55d7488593735b3aa4111426
3 N11812e1780ee4fbb90bc2a5e3fe40e99
4 N199948aeb4b346048f3ba911e23e3fa3
5 N2ce87acd9e5b4890b0699a25d6451bdb
6 N2d5a546cebd942ad81dc855d69919597
7 N3d7d742140724d289cd115091ababbb2
8 N4342ece51d5747cc8a2bfa29d4cca57a
9 N57ab7353b6554943a42f633fb0f29671
10 N625039556f9e428a888a4fdb270dd435
11 N6917da63b03646228637a08207438327
12 N6dc372db3a2d47d897b7e6ca80f242e7
13 N78e0034214f94ba58e11326977bfe991
14 N8499e78ebbdd4c9dadd681ad2fb6ee02
15 Nb12dc22873fe4093a786da6af3de39f0
16 Nb53c8b1c3aae4cc3823af3263439093a
17 Ncfb1c47a400a4794a52685a63652311d
18 Nfed6db7778c247ffb9df15a384c0c7b7
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author N62ae9d19efef4d93bc30d252581179a7
22 schema:citation sg:pub.10.1007/s10637-014-0091-8
23 sg:pub.10.1038/pcan.2015.53
24 https://app.dimensions.ai/details/publication/pub.1074847503
25 https://app.dimensions.ai/details/publication/pub.1082466113
26 https://doi.org/10.1016/0304-3959(75)90044-5
27 https://doi.org/10.1016/j.clgc.2014.06.001
28 https://doi.org/10.1016/j.ejca.2008.10.026
29 https://doi.org/10.1016/s0090-4295(99)00167-3
30 https://doi.org/10.1016/s0140-6736(10)61389-x
31 https://doi.org/10.1016/s1470-2045(10)70112-1
32 https://doi.org/10.1016/s1470-2045(12)70477-1
33 https://doi.org/10.1016/s1470-2045(13)70184-0
34 https://doi.org/10.1016/s1470-2045(13)70479-0
35 https://doi.org/10.1016/s1470-2045(15)70025-2
36 https://doi.org/10.1056/nejmoa040720
37 https://doi.org/10.1056/nejmoa041318
38 https://doi.org/10.1056/nejmoa060655
39 https://doi.org/10.1056/nejmoa065044
40 https://doi.org/10.1056/nejmoa1209096
41 https://doi.org/10.1056/nejmoa1213755
42 https://doi.org/10.1056/nejmoa1405095
43 https://doi.org/10.1093/annonc/mdm554
44 https://doi.org/10.1093/annonc/mdp111
45 https://doi.org/10.1111/j.1464-410x.2008.08327.x
46 https://doi.org/10.1200/jco.2007.12.4487
47 https://doi.org/10.1200/jco.2008.20.1293
48 https://doi.org/10.1200/jco.2011.39.4767
49 https://doi.org/10.1200/jco.2012.45.0494
50 https://doi.org/10.1200/jco.2012.46.4149
51 https://doi.org/10.1200/jco.2012.48.5268
52 https://doi.org/10.1200/jco.2014.57.3105
53 https://doi.org/10.2967/jnumed.112.105007
54 schema:datePublished 2016-12
55 schema:datePublishedReg 2016-12-01
56 schema:description Background Docetaxel is a standard first-line treatment option for men with metastatic castration resistant prostate cancer (mCRPC). Sunitinib is attractive as a maintenance therapy due to its mechanism of action, oral route of administration, and acceptable toxicity profile. We designed a phase II study of sunitinib in patients with mCRPC who responded to docetaxel. Methods Patients with responding or stable disease at the completion of docetaxel treatment received 50 mg of sunitinib on 4 week on 2 week off cycles. Treatment continued until disease progression (either by RECIST 1.1 criteria or by cancer related symptomatic progression), intolerable toxicity, start of new cancer therapy, withdrawal of consent, or death. The primary endpoint was progression free survival. Secondary endpoints included PSA response rate and safety. Results Twenty-three patients were enrolled and treated. The mean number of prior cycles of docetaxel given was 8.6 (range 4-12). The median number of cycles of sunitinib administered was 4 (range 1-11). Adverse events were generally grade 1-2 with 12 % grade ≥ 3 which were of a type and severity expected for sunitinib. Median PFS was 4.4 months (95 % CI: 1.6-5.1). Most patients had immediate PSA increases without other evidence of disease progression, with the mean increases in PSA over baseline being 197 %, 342 %, and 1437 % in Cycles 1, 2, and 3, respectively. Conclusion Sunitinib was tolerable as maintenance therapy but median PFS was significantly lower than the predefined threshold of 6 months.
57 schema:genre research_article
58 schema:inLanguage en
59 schema:isAccessibleForFree false
60 schema:isPartOf Ne3008b6b653a42f7b3bc09c605eadea9
61 Nf86800b41bac4a2989bb49cd6d31a6ca
62 sg:journal.1094201
63 schema:name Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)
64 schema:pagination 771-776
65 schema:productId N368b3ba9bc6043c08d74ffab656765fe
66 N54fb1cea1fa647a69651749e7366dbb8
67 N64327fc4fe2341b89418e1ee7cc65eaf
68 N9083678fe79a429e823b2d18ccd6e982
69 Nef7fc1f2aaaf42f1a5bdfa890ea7023a
70 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045234243
71 https://doi.org/10.1007/s10637-016-0386-z
72 schema:sdDatePublished 2019-04-11T12:43
73 schema:sdLicense https://scigraph.springernature.com/explorer/license/
74 schema:sdPublisher N22eba490cb674f06bc70ca64fb3f87fe
75 schema:url https://link.springer.com/10.1007%2Fs10637-016-0386-z
76 sgo:license sg:explorer/license/
77 sgo:sdDataset articles
78 rdf:type schema:ScholarlyArticle
79 N0211bb9d43e34d148dee27237e321534 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Indoles
81 rdf:type schema:DefinedTerm
82 N0226f7ec55d7488593735b3aa4111426 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Antineoplastic Combined Chemotherapy Protocols
84 rdf:type schema:DefinedTerm
85 N10fa6c171b8c410481c30610704bb097 rdf:first sg:person.01151470300.91
86 rdf:rest N767b765f0cbc41ad85dc83dba164db16
87 N11812e1780ee4fbb90bc2a5e3fe40e99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Survival Rate
89 rdf:type schema:DefinedTerm
90 N13104fc5b9534da1bc3d5f1cb0f6d777 rdf:first sg:person.01305315522.41
91 rdf:rest N31368e6711194a778a13a5f50cfeb445
92 N199948aeb4b346048f3ba911e23e3fa3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Follow-Up Studies
94 rdf:type schema:DefinedTerm
95 N22eba490cb674f06bc70ca64fb3f87fe schema:name Springer Nature - SN SciGraph project
96 rdf:type schema:Organization
97 N2ce87acd9e5b4890b0699a25d6451bdb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Disease Management
99 rdf:type schema:DefinedTerm
100 N2d5a546cebd942ad81dc855d69919597 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Bone Neoplasms
102 rdf:type schema:DefinedTerm
103 N31368e6711194a778a13a5f50cfeb445 rdf:first sg:person.01103355100.69
104 rdf:rest N9dd12574cf324172b2d3fe97ad83a963
105 N368b3ba9bc6043c08d74ffab656765fe schema:name nlm_unique_id
106 schema:value 8309330
107 rdf:type schema:PropertyValue
108 N3d7d742140724d289cd115091ababbb2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Lymphatic Metastasis
110 rdf:type schema:DefinedTerm
111 N4342ece51d5747cc8a2bfa29d4cca57a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Taxoids
113 rdf:type schema:DefinedTerm
114 N54fb1cea1fa647a69651749e7366dbb8 schema:name dimensions_id
115 schema:value pub.1045234243
116 rdf:type schema:PropertyValue
117 N57ab7353b6554943a42f633fb0f29671 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Docetaxel
119 rdf:type schema:DefinedTerm
120 N625039556f9e428a888a4fdb270dd435 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Humans
122 rdf:type schema:DefinedTerm
123 N62ae9d19efef4d93bc30d252581179a7 rdf:first sg:person.014436423575.89
124 rdf:rest N874cd130edd54589b3c3f84be8700fda
125 N64327fc4fe2341b89418e1ee7cc65eaf schema:name pubmed_id
126 schema:value 27565809
127 rdf:type schema:PropertyValue
128 N65e25e457aff43b0aebe6db645d8080b rdf:first sg:person.01031740163.39
129 rdf:rest Nc5f8ec709d3a4378a4948315c2589b80
130 N6917da63b03646228637a08207438327 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Prognosis
132 rdf:type schema:DefinedTerm
133 N6dc372db3a2d47d897b7e6ca80f242e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Prostatic Neoplasms, Castration-Resistant
135 rdf:type schema:DefinedTerm
136 N767b765f0cbc41ad85dc83dba164db16 rdf:first sg:person.01133654411.98
137 rdf:rest N65e25e457aff43b0aebe6db645d8080b
138 N78e0034214f94ba58e11326977bfe991 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Aged
140 rdf:type schema:DefinedTerm
141 N8499e78ebbdd4c9dadd681ad2fb6ee02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Pyrroles
143 rdf:type schema:DefinedTerm
144 N874cd130edd54589b3c3f84be8700fda rdf:first sg:person.011711467574.81
145 rdf:rest N10fa6c171b8c410481c30610704bb097
146 N9083678fe79a429e823b2d18ccd6e982 schema:name doi
147 schema:value 10.1007/s10637-016-0386-z
148 rdf:type schema:PropertyValue
149 N9dd12574cf324172b2d3fe97ad83a963 rdf:first sg:person.0767126500.90
150 rdf:rest rdf:nil
151 Nb12dc22873fe4093a786da6af3de39f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Male
153 rdf:type schema:DefinedTerm
154 Nb53c8b1c3aae4cc3823af3263439093a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Neoplasm Staging
156 rdf:type schema:DefinedTerm
157 Nc5f8ec709d3a4378a4948315c2589b80 rdf:first sg:person.01142252161.65
158 rdf:rest N13104fc5b9534da1bc3d5f1cb0f6d777
159 Ncfb1c47a400a4794a52685a63652311d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Sunitinib
161 rdf:type schema:DefinedTerm
162 Nd267a7f0cbc24012af290aa37ffdd2a0 schema:name Medicine Hat Cancer Centre, Medicine Hat, AB, Canada
163 rdf:type schema:Organization
164 Ne3008b6b653a42f7b3bc09c605eadea9 schema:issueNumber 6
165 rdf:type schema:PublicationIssue
166 Nef7fc1f2aaaf42f1a5bdfa890ea7023a schema:name readcube_id
167 schema:value d777a7e30058accb7be988300a600ae5048cd325c358721885dcf811f4ed9813
168 rdf:type schema:PropertyValue
169 Nf86800b41bac4a2989bb49cd6d31a6ca schema:volumeNumber 34
170 rdf:type schema:PublicationVolume
171 Nfed6db7778c247ffb9df15a384c0c7b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Middle Aged
173 rdf:type schema:DefinedTerm
174 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
175 schema:name Medical and Health Sciences
176 rdf:type schema:DefinedTerm
177 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
178 schema:name Oncology and Carcinogenesis
179 rdf:type schema:DefinedTerm
180 sg:journal.1094201 schema:issn 0167-6997
181 1573-0646
182 schema:name Investigational New Drugs
183 rdf:type schema:Periodical
184 sg:person.01031740163.39 schema:affiliation https://www.grid.ac/institutes/grid.412745.1
185 schema:familyName Winquist
186 schema:givenName Eric
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031740163.39
188 rdf:type schema:Person
189 sg:person.01103355100.69 schema:affiliation https://www.grid.ac/institutes/grid.413574.0
190 schema:familyName Cheng
191 schema:givenName Tina
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103355100.69
193 rdf:type schema:Person
194 sg:person.01133654411.98 schema:affiliation Nd267a7f0cbc24012af290aa37ffdd2a0
195 schema:familyName Trudeau
196 schema:givenName Marc
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133654411.98
198 rdf:type schema:Person
199 sg:person.01142252161.65 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
200 schema:familyName Chi
201 schema:givenName Kim N.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65
203 rdf:type schema:Person
204 sg:person.01151470300.91 schema:affiliation https://www.grid.ac/institutes/grid.17089.37
205 schema:familyName North
206 schema:givenName Scott
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151470300.91
208 rdf:type schema:Person
209 sg:person.011711467574.81 schema:affiliation https://www.grid.ac/institutes/grid.429997.8
210 schema:familyName Eliasziw
211 schema:givenName Misha
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011711467574.81
213 rdf:type schema:Person
214 sg:person.01305315522.41 schema:affiliation https://www.grid.ac/institutes/grid.413574.0
215 schema:familyName Ruether
216 schema:givenName Dean
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305315522.41
218 rdf:type schema:Person
219 sg:person.014436423575.89 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
220 schema:familyName Parimi
221 schema:givenName Sunil
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014436423575.89
223 rdf:type schema:Person
224 sg:person.0767126500.90 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
225 schema:familyName Eigl
226 schema:givenName Bernhard J.
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767126500.90
228 rdf:type schema:Person
229 sg:pub.10.1007/s10637-014-0091-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008660056
230 https://doi.org/10.1007/s10637-014-0091-8
231 rdf:type schema:CreativeWork
232 sg:pub.10.1038/pcan.2015.53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039566191
233 https://doi.org/10.1038/pcan.2015.53
234 rdf:type schema:CreativeWork
235 https://app.dimensions.ai/details/publication/pub.1074847503 schema:CreativeWork
236 https://app.dimensions.ai/details/publication/pub.1082466113 schema:CreativeWork
237 https://doi.org/10.1016/0304-3959(75)90044-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008265857
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1016/j.clgc.2014.06.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013259124
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1016/s0090-4295(99)00167-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015822531
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1016/s0140-6736(10)61389-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1005976220
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1016/s1470-2045(10)70112-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024596205
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1016/s1470-2045(12)70477-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009666173
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1016/s1470-2045(13)70184-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037354085
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1016/s1470-2045(13)70479-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027103739
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1016/s1470-2045(15)70025-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000667047
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1056/nejmoa040720 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029249997
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1056/nejmoa041318 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028543233
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1056/nejmoa060655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025111240
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1056/nejmoa065044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007947936
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1056/nejmoa1209096 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034543175
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1056/nejmoa1213755 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046224838
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1056/nejmoa1405095 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017836241
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1093/annonc/mdm554 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035066248
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1093/annonc/mdp111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002885649
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1111/j.1464-410x.2008.08327.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1006573530
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1200/jco.2007.12.4487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031178629
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1200/jco.2008.20.1293 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013684571
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1200/jco.2011.39.4767 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031092562
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1200/jco.2012.45.0494 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013364059
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1200/jco.2012.46.4149 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002989958
286 rdf:type schema:CreativeWork
287 https://doi.org/10.1200/jco.2012.48.5268 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037275515
288 rdf:type schema:CreativeWork
289 https://doi.org/10.1200/jco.2014.57.3105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044225328
290 rdf:type schema:CreativeWork
291 https://doi.org/10.2967/jnumed.112.105007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041669007
292 rdf:type schema:CreativeWork
293 https://www.grid.ac/institutes/grid.17089.37 schema:alternateName University of Alberta
294 schema:name Cross Cancer Institute, Edmonton, AB, Canada
295 rdf:type schema:Organization
296 https://www.grid.ac/institutes/grid.248762.d schema:alternateName BC Cancer Agency
297 schema:name Department of Medical Oncology, BC Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, V5Z 4E6, Vancouver, BC, Canada
298 rdf:type schema:Organization
299 https://www.grid.ac/institutes/grid.412745.1 schema:alternateName London Health Sciences Centre
300 schema:name London Regional Cancer Centre, London, ON, Canada
301 rdf:type schema:Organization
302 https://www.grid.ac/institutes/grid.413574.0 schema:alternateName Alberta Health Services
303 schema:name Tom Baker Cancer Centre, Calgary, AB, Canada
304 rdf:type schema:Organization
305 https://www.grid.ac/institutes/grid.429997.8 schema:alternateName Tufts University
306 schema:name Tufts University, Boston, MA, USA
307 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...